Clinical Trial Update: A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study of AIN457 (efalizumab) in adults with chronic plaque psoriasis has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Raptiva (efalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Plaque-type Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2015-02-16